MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
21.45
-0.31
-1.42%
After Hours: 21.40 -0.05 -0.23% 17:48 09/28 EDT
OPEN
21.57
PREV CLOSE
21.76
HIGH
21.93
LOW
21.00
VOLUME
824.58K
TURNOVER
--
52 WEEK HIGH
40.65
52 WEEK LOW
12.96
MARKET CAP
1.47B
P/E (TTM)
-8.9640
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TYRA last week (0921-0925)?
Weekly Report · 13h ago
Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Madrigal Pharmaceuticals (MDGL)
TipRanks · 4d ago
Is Tyra Biosciences (TYRA) Undervalued As Phase 2 Data And Fresh Funding Reset Expectations?
Simply Wall St · 5d ago
Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
TipRanks · 5d ago
Tyra Biosciences Price Target Cut to $40.00/Share From $50.00 by Oppenheimer
Dow Jones · 6d ago
Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40
Benzinga · 6d ago
Tyra Biosciences price target lowered to $40 from $50 at Oppenheimer
TipRanks · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiol Therapeutics (CRDL), Tyra Bioscience (TYRA) and Alibaba Health Information Technology (OtherALBHF)
TipRanks · 6d ago
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.